3.9 Article

Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID

Journal

HUMAN GENE THERAPY CLINICAL DEVELOPMENT
Volume 27, Issue 2, Pages 57-61

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/humc.2016.29010.ind

Keywords

-

Ask authors/readers for more resources

GlaxoSmithKline's (GSK) and partner San Raffaele Telethon Institute for Gene Therapy's recent positive European approval for Strimvelis for treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) represents the second EU-approved gene therapy and the first-retrovirus and first ex vivo gene therapy. In this article we discuss the significance and implications of this historic approval for the broader gene therapy field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available